Skip to main content
. 2022 Oct 25;305(3):512–525. doi: 10.1148/radiol.220585

Figure 6:

Images in a 69-year-old woman who presented with chronic cough. (A) Baseline whole-body fluorodeoxyglucose (FDG) PET scan (left) and fused axial FDG PET/CT image (right) show FDG-avid left perihilar lesion with extensive pleural metastasis (*) and osseous metastases (arrows) in the left pelvic bone, consistent with extensive small cell lung cancer. (B) Follow-up whole-body FDG PET scan (left) and fused axial FDG PET/CT scan (right) obtained after four cycles of therapy with carboplatin, etoposide, and atezolizumab demonstrate excellent response, with decreased tumor burden and residual FDG-avid disease in the left hilar region and pleura (arrowheads).

Images in a 69-year-old woman who presented with chronic cough. (A) Baseline whole-body fluorodeoxyglucose (FDG) PET scan (left) and fused axial FDG PET/CT image (right) show FDG-avid left perihilar lesion with extensive pleural metastasis (*) and osseous metastases (arrows) in the left pelvic bone, consistent with extensive small cell lung cancer. (B) Follow-up whole-body FDG PET scan (left) and fused axial FDG PET/CT scan (right) obtained after four cycles of therapy with carboplatin, etoposide, and atezolizumab demonstrate excellent response, with decreased tumor burden and residual FDG-avid disease in the left hilar region and pleura (arrowheads).